Arvinas logo

Patients

Smiling Arvinas scientific staff members working in Lab

Clinical Trials

Our clinical trials help to advance the understanding of innovative medicines and determine whether the new treatments are being developed are safe and effective.

We know that the decision to participate in clinical trial research is not made lightly, and we sincerely thank all the patients and families who choose to partake. Your physician is the best person to help you decide if a clinical trial or any other treatment option is right for you.

The agents listed below are currently under investigation. Their safety and effectiveness have not yet been established.

Smiling Arvinas scientific staff members working in Lab
Arvinas scientific staff member preparing vials for testing
Display of different lab materials used in testing

ARV-471 is an investigational orally bioavailable PROTAC® protein degrader designed to target and degrade the estrogen receptor (ER) for the treatment of patients with locally advanced or metastatic ER-positive / HER2-negative breast cancer.

ARV-471 is an investigational compound. It’s safety and efficacy has not been established.

 

Currently Recruiting:

 

 

If you’re interested in learning more about this trial, please speak with your doctor and visit the website www.clinicaltrials.gov


Collaborator:

Bavdegalutamide (ARV-110) is an investigational orally bioavailable PROTAC® protein degrader designed to selectively target and degrade the androgen receptor (AR). Bavdegalutamide is being developed as a potential treatment for men with metastatic castration-resistant prostate cancer (mCRPC).

 

Currently Recruiting:

 

 

 

If you’re interested in learning more about this trial, please speak with your doctor and visit the website www.clinicaltrials.gov

ARV-766 is an investigational orally bioavailable PROTAC® protein degrader designed to selectively target and degrade the androgen receptor (AR). ARV-766 is being developed as a potential treatment for men with metastatic castration-resistant prostate cancer (mCRPC).

 

Currently Recruiting:

 

 

If you’re interested in learning more about this trial, please speak with your doctor and visit the website www.clinicaltrials.gov

Skip to content